Pharmacovigilance Market Value Surpass USD 16.23 Billion by 2030

The global pharmacovigilance market size is estimated to generate revenues of more than USD 16.23 billion by 2030, growing at a CAGR of around 7.2% from 2022 to 2030

The report covers SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. The report offers an analysis of the global pharmacovigilance Market for the period 2017 to 2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.

The wide application portfolio of pharmacovigilance market is one of factors driving the growth of market worldwide. The global market is moderately competitive with a blend of global and regional players. The markets key players invest significantly in R and D to enhance their offerings. The entire ecosystem is composed of multiple participants. Every participant of the ecosystem is an equal contributor to the growth of global market.

Why should you invest in this report?

If you are aiming to enter the global pharmacovigilance Market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for pharmacovigilance are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly. Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

 

Report Structure:

• pertinent market numbers of the global pharmacovigilance market along with the CAGR for the forecast period 2022-2030
• detailed definitions of different types of pharmacovigilance, which gives clarity about what this market is all about and also defines the scope of this report
• macroeconomic factors influencing the global pharmacovigilance market, along with market opportunity analysis
• key trends likely to impact the global pharmacovigilance market
• PESTLE analysis of all the regions as per the market taxonomy
• Porter’s Five Force Analysis of all the regions as given in the market taxonomy

Global market analysis and forecast:

• the global pharmacovigilance market analysis and forecast by product type, by application, by region and others
• key market metrics such as the BPS analysis, year-on-year growth rates, absolute dollar opportunity and market attractiveness analysis of the global pharmacovigilance market

Regional market analysis and forecast:

• Regional pharmacovigilance market analysis and forecast
• Regional market dynamics including the drivers, restraints and trends applicable across different regions in the pharmacovigilance market along with factors encouraging the growth of this market as well as the factors hampering the growth of this market
• Regional trends – both long term and short term

View Full Report@ https://www.precedenceresearch.com/pharmacovigilance-market

Competitive landscape:

• the competitive landscape of this global report
• information on the various leading companies in the global market
• a dashboard view of the key companies operating in the global market along with their important information and broad strategy adopted to stay as leaders in the global market
• key company profiles along with important information such as company details, company description, product portfolio along with key developments concerning the company and strategic analysis

Some of the prominent players in pharmacovigilance market include:

• ICON Plc
• Pharmaceutical Product Development LLC
• Parexel International Corporation
• IQVIA
• Quanticate
• Bioclinica
• Covance Inc.
• Accenture Plc
• IBM Corporation
• Novartis

Market Segmentation:

By Clinical Trial Phase

• Preclinical Phase I
• Phase II
• Phase III
• Phase IV

By Service Provider

• In-house
• Contract Outsourcing

By End User

• Hospitals
• Pharmaceutical Companies
• Others

By Therapeutic Area

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

By Type

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

By Process Flow

• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Reviewing & Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review & Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of the World

Research Methodology

In this report, historical data, primary responses and public domain data has been thoroughly analyzed to infer the market size. Revenue of companies operating in the global market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to determine the market size for the forecast period. The historical growth trend of end-use industries, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and extensively scrutinized using advanced tools to garner quantitative and qualitative insights into the global pharmacovigilance.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Process Flow Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmacovigilance Market 

5.1. COVID-19 Landscape: Pharmacovigilance Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmacovigilance Market, By Clinical Trial Phase

8.1. Pharmacovigilance Market, by Clinical Trial Phase Type, 2021-2030

8.1.1. Preclinical Phase I

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Pharmacovigilance Market, By Service Provider Type

9.1. Pharmacovigilance Market, by Service Provider Type, 2021-2030

9.1.1. In-house

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Contract Outsourcing

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Pharmacovigilance Market, By End User

10.1. Pharmacovigilance Market, by End User Type, 2021-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Pharmaceutical Companies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Pharmacovigilance Market, By Therapeutic Area

11.1. Pharmacovigilance Market, by Therapeutic Area Type, 2021-2030

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Neurology

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Cardiology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Respiratory Systems

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Pharmacovigilance Market, By Type

12.1. Pharmacovigilance Market, by Type, 2021-2030

12.1.1. Spontaneous Reporting

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Intensified ADR Reporting

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Targeted Spontaneous Reporting

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Cohort Event Monitoring

12.1.4.1. Market Revenue and Forecast (2017-2030)

12.1.5. EHR Mining

12.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Pharmacovigilance Market, By Process Flow

13.1. Pharmacovigilance Market, by Service Provider Type, 2021-2030

13.1.1. Case Data Management

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Signal Detection

13.1.2.1. Market Revenue and Forecast (2017-2030)

13.1.3. Risk Management System

13.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Pharmacovigilance  Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.1.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.1.3. Market Revenue and Forecast, by End User (2017-2030)

14.1.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.1.5. Market Revenue and Forecast, by Type (2017-2030)

14.1.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.1.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.1.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.1.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.1.8. Market Revenue and Forecast, by Type (2017-2030)

14.1.8.1. Market Revenue and Forecast, by Process Flow (2017-2030) 

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.1.9.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.1.9.3. Market Revenue and Forecast, by End User (2017-2030)

14.1.9.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.1.10. Market Revenue and Forecast, by Type (2017-2030)

14.1.11. Market Revenue and Forecast, by Process Flow (2017-2030)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030) 

14.2.5. Market Revenue and Forecast, by Type (2017-2030)

14.2.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.8.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.8.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.9. Market Revenue and Forecast, by Therapeutic Area (2017-2030) 

14.2.10. Market Revenue and Forecast, by Type (2017-2030)

14.2.10.1. Market Revenue and Forecast, by Process Flow (2017-2030) 

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.11.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.11.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.12. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.2.13. Market Revenue and Forecast, by Type (2017-2030)

14.2.14. Market Revenue and Forecast, by Process Flow (2017-2030)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.15.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.15.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.15.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.2.16. Market Revenue and Forecast, by Type (2017-2030)

14.2.16.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.17.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.17.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.17.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.2.18. Market Revenue and Forecast, by Type (2017-2030)

14.2.18.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.5. Market Revenue and Forecast, by Type (2017-2030)

14.3.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.8. Market Revenue and Forecast, by Type (2017-2030)

14.3.9. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.10.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.10.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.10.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.11. Market Revenue and Forecast, by Type (2017-2030)

14.3.11.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.12.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.12.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.12.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.12.5. Market Revenue and Forecast, by Type (2017-2030)

14.3.12.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.13.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.13.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.13.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.13.5. Market Revenue and Forecast, by Type (2017-2030)

14.3.13.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.5. Market Revenue and Forecast, by Type (2017-2030)

14.4.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.8. Market Revenue and Forecast, by Type (2017-2030)

14.4.9. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.10.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.10.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.10.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.11. Market Revenue and Forecast, by Type (2017-2030)

14.4.12. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.13.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.13.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.13.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.13.5. Market Revenue and Forecast, by Type (2017-2030)

14.4.13.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.14.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.14.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.14.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.14.5. Market Revenue and Forecast, by Type (2017-2030)

14.4.14.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.5.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.5.3. Market Revenue and Forecast, by End User (2017-2030)

14.5.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.5.5. Market Revenue and Forecast, by Type (2017-2030)

14.5.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.5.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.5.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.5.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.5.8. Market Revenue and Forecast, by Type (2017-2030)

14.5.8.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.5.9.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.5.9.3. Market Revenue and Forecast, by End User (2017-2030)

14.5.9.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.5.9.5. Market Revenue and Forecast, by Type (2017-2030)

14.5.9.6. Market Revenue and Forecast, by Process Flow (2017-2030)

Chapter 15. Company Profiles

15.1. ICON Plc

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pharmaceutical Product Development LLC

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Parexel International Corporation

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. IQVIA

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Quanticate

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bioclinica

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Covance Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Accenture Plc

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. IBM Corporation

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Novartis

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms         

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333      

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Blog: http://www.marketstatsnews.com/

Follow us on LinkedIn | Twitter | Facebook